Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754368 | 0.89 | NPC1 (0.44) | HDAC6SMN1; SMN2HDAC1MEN1KMT2A | |
| SCHEMBL6813351 | 0.87 | HDAC6 (0.40) | HDAC6SMN1; SMN2HDAC1MEN1KMT2A | |
| SCHEMBL6704736 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPT | |
| SCHEMBL6706175 | 0.84 | HDAC6 (0.40) | HDAC6SMN1; SMN2HDAC1MAPTHTT | |
| SCHEMBL6704915 | 0.82 | ERCC5 (0.44) | — | |
| SCHEMBL6704944 | 0.79 | THRB (0.45) | HDAC6SMN1; SMN2HDAC1MAPTPKM | |
| SCHEMBL6753604 | 0.77 | POLB (0.43) | HDAC6SMN1; SMN2HDAC1KMT2ARAB9A | |
| SCHEMBL6706798 | 0.74 | MAPT (0.55) | SMN1; SMN2MAPT | |
| SCHEMBL6765613 | 0.73 | MEN1 (0.52) | HDAC6SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL6742554 | 0.70 | PTGER4 (0.48) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | NAHRA JOE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014869-A2 | 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | PTGS2 261/4885HDAC6 372/4885SMN1; SMN2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.